Etanercept is beneficial in controlling the mucocutaneous lesions of Behcet's syndrome (BS) at short term but does not suppress the pathergy reaction and the cutaneous response to intradermally injected monosodium urate (MSU) crystals: A double blind placebo controlled trial.